This company has been steadily moving up in the last month after sealing a 95m deal with a major pharmaceutical , good press on the weekend is now making it move ahead.

Brokers target is short term 40p.

DYOR

Just as an update SR Pharma are now 38p and will go on through 40p next week onto next level of 60p.

I don't believe any other share has had this percentage rise on volume over the last 10 days.

Now 40.5p , between 6 Nov and today has reached the initial broker target of 40p from 18.5p and is now moving to next broker target of 60p.

Strange how theres no posts , are people embarrassed they didn't take notice of my first few posts.

SCORCH, is that 20,000 short from 08:21 hrs going to get burnt?

Canada1

Seeing as it is now up 21% today to 46p I think anyone shorting this at the moment is mad.

I won't be surprised to see 60p next week after it has gone up 8p alone today.

..

is this part of the ERX RGT SPA PYC take over roche are putting in place..

The belief is that a large pharma company is tracking SPA , especially as they have the deal with Pfizer in the bag with possible income of 95m dollars in milestone payments as well as royalties.

Still no sign of SPA slowing down now up to 46.5p mostly buys

Shares mag have today stated that the SPA share price still has got a long way to go with a price target of 73p , currently 43p.

Offer now 53.5p it's more than tripled since the beginning of November and will continue to rise on good news about latest trials.

Well on its way to 73p price target , currently 64.5p . More than tripled in last 2 months and will not be surprised to see it go over 100p after next set of news reports on its cancer technology.

anybody know why SPA moving so sharply today?

quiet on here but a good company to watch.........news coming shortly from what ive heard...;o)

Bad news though...


SR Pharma annual losses widen
AFX

LONDON (AFX) - SR Pharma PLC, which specialises in RNAi-based therapeutics, reported widening annual losses on higher research and development costs, and forecast a significant hike in spending this year.

The company also said it plans to change its name to Silence Therapeutics.

Pretax losses in 2006 came in at 3.9 mln stg, compared to 3.6 mln the previous year.

Revenues surged four-fold to 1.95 mln stg, while R&D spend almost doubled to 3.2 mln stg.

During 2007 the group is forecasting a significant increase in R&D and infrastructure costs, as its lead molecules move into the clinic for human testing, and as US operations are set up.

SR Pharma said those costs will be funded through a continuation of collaboration and licensing deals with major pharmaceutical and biotechnology companies, on which it is in talks with a number of potential parties.

The company has called an Extraordinary General Meeting to approve the name change, and permission to issue new shares.

The group ended the year with 8.8 mln stg in cash.

SR Pharma shares, which have surged 440 pct in the last six months, closed Thursday at 81 pence, valuing the company at 92 mln stg.

Price now 92.75p and rising , this is going to be the best performing share on aim.

have to agree Scorch....been in since 22p...;o)

hlyeo98....yoo should take a look at the advfn thread....lots of good info there....most of it true from what i can gather...;o)